secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001104659-24-130002
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics: 78% objective response in APOLLO study; raises $16.1M in private placement
--------------------------------------------------------------------------------

- Phase 1 APOLLO: 78% of patients (7/9) achieved objective response; 44.4% complete response at first assessment.
- MT-601 well tolerated; no ICANS observed, one Grade 1 CRS; no dose-limiting toxicities.
- Private placement raises $16.1M gross proceeds; 5,031,250 shares at $3.20 with warrants at $4.03.
- Proceeds to support clinical advancement of MT-601 in relapsed lymphoma after CAR-T failure.
- New and existing investors: Blue Owl, NEA, and Aisling Capital participated in the financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924130002/0001104659-24-130002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924130002/tm2431560d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-130002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer